Abstract
Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Current Psychopharmacology
Title:Interrelation of Major Depression and Antidepressant Transcriptomics
Volume: 1
Author(s): Jurgen Zschocke, Nils Christian Gassen and Theo Rein
Affiliation:
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Abstract: Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Export Options
About this article
Cite this article as:
Zschocke Jurgen, Christian Gassen Nils and Rein Theo, Interrelation of Major Depression and Antidepressant Transcriptomics, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040284
DOI https://dx.doi.org/10.2174/2211556011201040284 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteoinductive Small Molecules: Growth Factor Alternatives for Bone Tissue Engineering
Current Pharmaceutical Design Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP): Novel Regulators of Ca 2+-Signaling and Cell Function
Current Molecular Medicine The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Evaluating the Diagnostic and Chemotherapeutic Potential of Vancomycin- Derived Imaging Conjugates
Medicinal Chemistry Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals The Use of Inorganic Compounds in Photodynamic Therapy: Improvements in Methods and Photosensitizer Design
Recent Patents on Nanotechnology Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis